DeutschNewstral
Article
bizjournals.com on 2020-12-02 21:25
Peninsula startup snares potential $1B Big Pharma deal focused on the 'undruggable'
Related news
- Peninsula startup snares potential $1B Big Pharma deal focused on the 'undruggable'bizjournals.com
- Peninsula cancer drug maker lands $1.2 billion Big Pharma dealbizjournals.com
- Why this Big Pharma wants to expand its Peninsula incubatorbizjournals.com
- Fresh off a $120M deal with Big Pharma, Peninsula biotech seeks to raise another $69Mbizjournals.com
- Peninsula biotech, Big Pharma ink $700M upfront deal around neurodegenerative diseasesbizjournals.com
- Big Pharma spinout on Peninsula targets childhood liver diseases, $86M IPObizjournals.com
- Big Pharma trims projects — and a potential $1 billion in payments — from collaboration with small Peninsula biotechbizjournals.com
- Can the nose point the way to early lung cancer detection? This Peninsula company's Big Pharma deal aims to find outbizjournals.com
Celonis snares $1B Series D on $11B valuationTechCrunch- Hasura snares $1.6 M seed for developer-focused Kubernetes solutionTechCrunch
- With focus on the 'undruggable,' Peninsula biotech raises $88.5M from IPO-minded investorsbizjournals.com
- Alzheimer's-focused Peninsula biotech raises $100Mbizjournals.com
- Peninsula startup Seer snares $55M toward launch of protein revolutionbizjournals.com
- Allergan snares Bay Area drug maker for potential $1.7 billionbizjournals.com
- Peninsula biotech snares $125M upfront payment in drug deal with Lillybizjournals.com
- Potential Peninsula biotech IPO lands $46 millionbizjournals.com
- Early cancer detection race heats up as Peninsula company snares $270Mbizjournals.com
Potential Fraud with H-1B Registration Submissionsjdsupra.com
US B-1B bombers conduct exercise over Korean Peninsulaspartanecho.org